Pulse.

a daily field guide to health research that matters

◆ Console

‹ Thu · 5 Nov 2026
Promising but preliminary

Real-world safety profile of finerenone in patients with type 2 diabetes and chronic kidney disease: a multi-database pharmacovigilance analysis of the FAERS and JADER systems.

Real-world safety data confirms finerenone protects kidney and heart health in diabetic patients with minimal unexpected adverse effects.

Finerenone, a novel nonsteroidal mineralocorticoid receptor antagonist, has been shown to lower the risk of renal and cardiovascular events in patients with type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD). A total of 1,545 (FAERS) and 210 (JADER) reports with finerenone as the primary suspect were identified.

What the study was

Study design
Clinical Trial
Population
Patients with (see abstract)
Category
Treatment Innovation
Maturity
Validated
Journal
Frontiers in clinical diabetes and healthcare

Why it surfaced

Design: Clinical Trial; Topics: Cardiovascular-metabolic: GLP-1, SGLT2, cardiometabolic risk; Species: human. Score=6/10.

A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.